- Home
- BDJ vs NRIX Comparison
BDJ vs NRIX Comparison
Compare BDJ & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDJ | NRIX |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BDJ | NRIX |
|---|---|---|
| Price | $9.51 | $19.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $29.08 |
| AVG Volume (30 Days) | 561.6K | ★ 1.4M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,687,000.00 |
| Revenue This Year | N/A | $59.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.32 |
| 52 Week Low | $6.91 | $8.18 |
| 52 Week High | $8.66 | $22.50 |
Technical Indicators
Market Signals| Indicator | BDJ | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 57.83 |
| Support Level | $9.47 | $17.97 |
| Resistance Level | $9.62 | $19.55 |
| Average True Range (ATR) | 0.09 | 0.98 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 68.49 | 76.22 |
Price Performance
Historical ComparisonAbout BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.